Antiangiogenic therapies for mesothelioma.
A large body of preclinical evidence suggests that angiogenesis plays a key role in the pathogenesis of malignant mesothelioma. Several mediators of angiogenesis seem to be autocrine growth factors in mesothelioma, and in preclinical models, agents that target angiogenesis produce tumor regression. Several clinical trials are currently evaluating the efficacy of inhibitors of angiogenesis in mesothelioma. This article details the preliminary results of these trials and future directions.
Dowell
Jonathan E
JE
University of Texas-Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8852, USA. jonathan.dowell@utsouthwestern.edu
Kindler
Hedy Lee
HL
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors